The deal, which was formally signed on the sidelines of the World Cancer Congress in Geneva this week, marks the first time a pharmaceutical company is making a patented cancer medicine available through a voluntary licensing scheme. “This is important because it’s the first and helps show that voluntary licences can work for cancer drugs,” Charles Gore, the executive director of the Medicines Patent Pool (MPP), told SWI swissinfo.ch.
Swiss pharma giant Novartis has finalised a deal to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
Comments are closed.